|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here we evaluated the clinical outcomes of DAPT guided by CYP2C19 polymorphisms after implantation of second-generation drug-eluting stents (DESs) for ACS management.
|
29279531 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We genotyped eight common PEAR1 SNPs (rs2768759, rs12566888, rs12041331, rs11264579, rs2644592, rs822441, rs822442, and rs4661012), also CYP2C19*2 (rs4244285) and CYP2C19*3 (rs4986893) in 196 Chinese patients with ACS.
|
29407631 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients hospitalized for ACS were randomly assigned to standard of care or the pharmacogenomic arm, which included the genotyping of ABCB1, CYP2C19*2, and CYP2C19*17 using an ST Q3 system that provides data within 70 min at each patient's bedside.
|
29540324 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim of this pilot prospective study was to evaluate 12-month cardiovascular outcomes in elderly patients with acute coronary syndrome (ACS) receiving dual antiplatelet therapy (aspirin and clopidogrel) according to the clustering of CYP2C19 and ABCB1 genetic variants.
|
29936693 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
<i>CYP2C19*2</i> and <i>CYP2C19*17</i> carrier status correlates with PR in ACS patients treated with clopidogrel and thus might be useful for pre-selecting patients who will and who may not be suitable for PGDE of anti-platelet treatment.
|
30103241 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results highlight that CYP2C19*2, along with diabetes, and use of proton pump inhibitor and statin are important factors jointly associated with variability in clinical response to DAPT following ACS in Egyptians.
|
30188374 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
CYP2C19 metabolizer status and GRACE score are readily available predictive approaches for MACEs, and their combination derives a more accurate long-term MACE prediction in clopidogrel-treated patients with ACS undergoing PCI.
|
30193195 |
2018 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Compared to clopidogrel, prasugrel produced a stable platelet aggregation inhibitory effect in patients with ACS regardless of CYP2C19 genotype, reduced cardiac enzyme release, and prevented cardiac remodeling after ACS.
|
30983087 |
2020 |
|
Acute Chest Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six strategies for selection of P2Y<sub>12</sub> inhibitors in ACS were compared from the US healthcare system perspective: (1) clopidogrel for all (universal clopidogrel); (2) ticagrelor guided by platelet reactivity assay (PRA; clopidogrel + phenotype); (3) ticagrelor use only in CYP2C19 poor metabolizers (genotype + conservative ticagrelor); (4) ticagrelor use in both CYP2C19 intermediate and poor metabolizers (genotype + liberal ticagrelor); (5) ticagrelor use only in patients with CYP2C19 polymorphisms and clopidogrel nonresponse by PRA (genotype + phenotype); and (6) ticagrelor for all (universal ticagrelor).
|
31367811 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Presence of specific CYP2C19 allele significantly influences clopidogrel metabolism and associated outcomes in patients with ACS.
|
31498157 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The null allele in the CYP2C19 (rs4244285) [odds ratio (OR)=5.317, 95% confidence interval (CI) 1.542-26.428, P=0.001] and CYP2C19 (rs4986893) (OR=4.295, 95%CI 1.312-17.517, P=0.013) is one of the causes of CR in patients with ACS in China.
|
31543510 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CYP2C19 G681A polymorphism and omeprazole use were both known for retarding the effects of clopidogrel under broad cardiovascular conditions; however, data from ACS patients were limited.
|
31658140 |
2019 |
|
Acute Chest Syndrome
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CYP2C19 and PON1 Q192R variants influence ADP-induced platelet inhibition by thrombelastography (TEG) in ACS patients with clopidogrel.
|
31772608 |
2019 |